Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFCD 2006 – NEORAF
2024-514107-34-00Phase 2Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib and cetuximab in colorectal adenocarcinoma, colon adenocarcinoma and rectal adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Safety and feasibility of neoadjuvant encorafenib and cetuximab. Planned start Jul 2024; status: authorised.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal adenocarcinomacolon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2024-514107-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514107-34-00.